Abstract:Type 2 diabetes mellitus (T2DM) is a chronic disease, and most patients ultimately require two or more anti-hyperglycemic drugs along with lifestyle changes to achieve and maintain glycaemic control. Sodium-glucose cotransporter 2(SGLT2) inhibitors, such as Dapagliflozin, are the newest class of antidiabetic drugs approved for the treatment of T2DM. Dapagliflozin is a highly selective SGLT2 inhibitor that decreases glucose reabsorption by kidneys and thus lowers blood glucose by increasing glucose excretion in… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.